313 related articles for article (PubMed ID: 32125100)
21. Tumor Necrosis Factor Inhibitor Primary Failure Predicts Decreased Ustekinumab Efficacy in Psoriasis Patients.
Sorensen EP; Fanucci KA; Saraiya A; Volf E; Au SC; Argobi Y; Mansfield R; Gottlieb AB
J Drugs Dermatol; 2015 Aug; 14(8):893-8. PubMed ID: 26267736
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of ustekinumab in the treatment of moderate to severe plaque psoriasis in Singapore.
Chan WSA; Wong Y; Oon HHB; Theng CTS; Chong WS
Singapore Med J; 2023 Jul; 64(7):434-438. PubMed ID: 35196847
[TBL] [Abstract][Full Text] [Related]
23. Structure-function relationship of tumor necrosis factor (TNF) and its receptor interaction based on 3D structural analysis of a fully active TNFR1-selective TNF mutant.
Mukai Y; Shibata H; Nakamura T; Yoshioka Y; Abe Y; Nomura T; Taniai M; Ohta T; Ikemizu S; Nakagawa S; Tsunoda S; Kamada H; Yamagata Y; Tsutsumi Y
J Mol Biol; 2009 Jan; 385(4):1221-9. PubMed ID: 19084540
[TBL] [Abstract][Full Text] [Related]
24. The Association between Clinical Response to Ustekinumab and Immunogenicity to Ustekinumab and Prior Adalimumab.
Chiu HY; Chu TW; Cheng YP; Tsai TF
PLoS One; 2015; 10(11):e0142930. PubMed ID: 26566272
[TBL] [Abstract][Full Text] [Related]
25. The influence of ustekinumab on expression of STAT1, STAT3, STAT4, SOCS2, and IL17 in patients with psoriasis and in a control.
Grabarek B; Krzaczyński J; Strzałka-Mrozik B; Wcisło-Dziadecka D; Gola J
Dermatol Ther; 2019 Sep; 32(5):e13029. PubMed ID: 31330078
[TBL] [Abstract][Full Text] [Related]
26. Tumor necrosis factor-alpha and its receptors contribute to apoptosis of oligodendrocytes in the spinal cord of spinal hyperostotic mouse (twy/twy) sustaining chronic mechanical compression.
Inukai T; Uchida K; Nakajima H; Yayama T; Kobayashi S; Mwaka ES; Guerrero AR; Baba H
Spine (Phila Pa 1976); 2009 Dec; 34(26):2848-57. PubMed ID: 19949368
[TBL] [Abstract][Full Text] [Related]
27. Indirect Regulation and Equilibrium of p35 and p40 Subunits of Interleukin (IL)-12/23 by Ustekinumab in Psoriasis Treatment.
Zhou J; Shen JY; Liu LF; Chen JS; Dou TT; Zheng M; Cai SQ
Med Sci Monit; 2020 Jan; 26():e920371. PubMed ID: 31910201
[TBL] [Abstract][Full Text] [Related]
28. Comparative effectiveness of adalimumab versus ustekinumab in the treatment of severe chronic plaque psoriasis: The results based on data from the program "treatment of moderate and severe forms of plaque psoriasis (B.47)" of the National Health Fund in Poland.
Owczarek W; Nowakowska A; Walecka I; Ciechanowicz P; Reich A; Lesiak A; Borkowska E; Śliwczyński A; Narbutt J
Dermatol Ther; 2022 Jun; 35(6):e15481. PubMed ID: 35363386
[TBL] [Abstract][Full Text] [Related]
29. Lowering Interleukin-12 Activity Improves Myocardial and Vascular Function Compared With Tumor Necrosis Factor-a Antagonism or Cyclosporine in Psoriasis.
Ikonomidis I; Papadavid E; Makavos G; Andreadou I; Varoudi M; Gravanis K; Theodoropoulos K; Pavlidis G; Triantafyllidi H; Moutsatsou P; Panagiotou C; Parissis J; Iliodromitis E; Lekakis J; Rigopoulos D
Circ Cardiovasc Imaging; 2017 Sep; 10(9):. PubMed ID: 28899951
[TBL] [Abstract][Full Text] [Related]
30. Effects of tumor necrosis factor-α, interleukin-23 and interleukin-17A inhibitors on bodyweight and body mass index in patients with psoriasis.
Takamura S; Takahashi A; Inoue Y; Teraki Y
J Dermatol; 2018 Sep; 45(9):1130-1134. PubMed ID: 30004583
[TBL] [Abstract][Full Text] [Related]
31. Bilateral muscle fiber and nerve influences by TNF-alpha in response to unilateral muscle overuse - studies on TNF receptor expressions.
Renström L; Stål P; Song Y; Forsgren S
BMC Musculoskelet Disord; 2017 Nov; 18(1):498. PubMed ID: 29183282
[TBL] [Abstract][Full Text] [Related]
32. Effect of Yinxieling decoction on PASI, TNF-α and IL-8 in patients with psoriasis vulgaris.
Dai YJ; Li YY; Zeng HM; Liang XA; Xie ZJ; Zheng ZA; Pan QH; Xing YX
Asian Pac J Trop Med; 2014 Aug; 7(8):668-670. PubMed ID: 25149384
[TBL] [Abstract][Full Text] [Related]
33. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.
Griffiths CE; Strober BE; van de Kerkhof P; Ho V; Fidelus-Gort R; Yeilding N; Guzzo C; Xia Y; Zhou B; Li S; Dooley LT; Goldstein NH; Menter A;
N Engl J Med; 2010 Jan; 362(2):118-28. PubMed ID: 20071701
[TBL] [Abstract][Full Text] [Related]
34. The role of TNF-alpha and its receptors in the production of beta-1,4-galactosyltransferase I mRNA by rat primary type-2 astrocytes.
Yan M; Xia C; Niu S; Cheng C; Shao X; Shen A
Cell Mol Neurobiol; 2008 Feb; 28(2):223-36. PubMed ID: 17712626
[TBL] [Abstract][Full Text] [Related]
35. Effects of bovine tumor necrosis factor alpha decoy receptors on cell death and inflammatory cytokine kinetics: potential for bovine inflammation therapy.
Fujisawa S; Konnai S; Okagawa T; Maekawa N; Tanaka A; Suzuki Y; Murata S; Ohashi K
BMC Vet Res; 2019 Feb; 15(1):68. PubMed ID: 30819151
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic Efficacy of Interleukin 12/Interleukin 23 Blockade in Generalized Pustular Psoriasis Regardless of IL36RN Mutation Status.
Arakawa A; Ruzicka T; Prinz JC
JAMA Dermatol; 2016 Jul; 152(7):825-8. PubMed ID: 27096382
[TBL] [Abstract][Full Text] [Related]
37. Role of tumor necrosis factor-α and its receptors in diesel exhaust particle-induced pulmonary inflammation.
Kumar S; Joos G; Boon L; Tournoy K; Provoost S; Maes T
Sci Rep; 2017 Sep; 7(1):11508. PubMed ID: 28912506
[TBL] [Abstract][Full Text] [Related]
38. New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinumab.
Kurzeja M; Rudnicka L; Olszewska M
Am J Clin Dermatol; 2011 Apr; 12(2):113-25. PubMed ID: 21348542
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).
Papp KA; Langley RG; Lebwohl M; Krueger GG; Szapary P; Yeilding N; Guzzo C; Hsu MC; Wang Y; Li S; Dooley LT; Reich K;
Lancet; 2008 May; 371(9625):1675-84. PubMed ID: 18486740
[TBL] [Abstract][Full Text] [Related]
40. TNFR2 unlocks a RIPK1 kinase activity-dependent mode of proinflammatory TNFR1 signaling.
Siegmund D; Ehrenschwender M; Wajant H
Cell Death Dis; 2018 Sep; 9(9):921. PubMed ID: 30206205
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
